Cyproterone acetate in the treatment of metastatic cancer of the male breast.

Abstract

Ten male patients with advanced cancer of the breast were treated with cyproterone acetate, an anti-androgenic compound with additional progestational properties. Seven patients achieved a response, for a median duration of 8 months. Plasma testosterone and estradiol levels fell significantly during therapy, but quantitatively this drop was not related to the therapeutic response. Cyproterone acetate is an effective and well-tolerated treatment for metastatic male breast cancer.

• Authors: M Lopez
• Journal: Cancer (Cancer) Vol. 55 Issue 10 Pg. 2334-6 (May 15 1985) ISSN: 0008-543X [Print] United States
• PMID: 3986737 (Publication Type: Journal Article)

Chemical References

• Testosterone
• Estradiol
• Prolactin
• Cyproterone

Topics

• Aged
• Breast Neoplasms (blood, drug therapy)
• Cyproterone (adverse effects, therapeutic use)
• Drug Evaluation
• Erectile Dysfunction (chemically induced)
• Estradiol (blood)
• Humans
• Male
• Middle Aged
• Neoplasm Metastasis
• Prolactin (blood)
• Testosterone (blood)